Cart
sales@molnova.com
Home - Products - Angiogenesis - JAK - JAK-IN-5

JAK-IN-5

CAS No. 2096999-92-5

JAK-IN-5( —— )

Catalog No. M26263 CAS No. 2096999-92-5

JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 371 Get Quote
10MG 552 Get Quote
25MG 879 Get Quote
50MG 1188 Get Quote
100MG 1602 Get Quote
500MG 3204 Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    JAK-IN-5
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
  • Description
    JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
  • In Vitro
    ——
  • In Vivo
    JAK-IN-5 (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction.JAK-IN-5 (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2096999-92-5
  • Formula Weight
    474.584
  • Molecular Formula
    C27H31FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CN(CCc2[nH]1)C1CCN(C)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhao H, Liu Q et al. In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells. Cancer Med. 2017 Jul;6(7):1698-1706.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JAK3-IN-2

    A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM.

  • Lorpucitinib

    Lorpucitinib (JNJ-64251330) is an orally available, selective and potent JAK kinase inhibitor for the study of inflammatory and gastrointestinal disorders associated with Janus kinase (JAK) signaling.

  • PF-06700841 tosylate

    PF-06700841 is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2.

Sign In Join Free